Not yet recruitingNot applicableNCT06748950
Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling
Studying Other metabolic disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Stanford University
- Principal Investigator
- Shebani Sethi, MD, ABOMStanford University
- Intervention
- LCHF Ketogenic Diet(other)
- Enrollment
- 120 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2025 – 2028
Study locations (1)
- Stanford University, Palo Alto, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06748950 on ClinicalTrials.gov